• Tianchi Tang, Yang Liu, Min Yang, Ming Tu, Wanchun Zhu, and Ming Chen.
• Department of Neurosurgery, Xinhua Hospital of Shanghai Jiaotong University School of Medicine, Shanghai, China.
• World Neurosurg. 2021 Oct 1; 154: e616-e626.

BackgroundGlycolysis is an important metabolic manner in glioblastoma multiforme (GBM)'s rapid growth. It has been reported that glutamate-oxaloacetate transaminase 1 (GOT1) is low-expressed in GBM and patients with high-expressed GOT1 have better prognosis. However, the effect and mechanism of GOT1 on glycolysis and malignant phenotypes of GBM cells are still unclear.MethodsThe expression differences of GOT1 between GBM parenchyma and adjacent tissues were detected. The prognosis and clinical data with different levels of GOT1 were also analyzed. The glucose consumption, production of lactate and pyruvate were measured after GOT1 was knocked down or overexpressed. The effects of GOT1 on GBM cell's malignant phenotypes were analyzed by Western blot, CCK-8 assay, and flow cytometry. The relationship between GOT1 and pyruvate carboxylase (PC) was examined by immunoprecipitation and immunofluorescence.ResultsGOT1 was expressed little in GBM, and patients with highly expressed GOT1 had longer survival periods. Overexpressed GOT1 inhibited the glycolysis and malignant phenotypes of GBM cells. 2-DG treatment could partially reverse the enhancement of malignant phenotypes caused by knockdown of GOT1. The expression of GOT1 was positively correlated with PC. The inhibitory effect of GOT1 on glycolysis could be partially reversed by PC's knockdown.ConclusionsGOT1 could impair glycolysis by interacting with PC and further inhibit the malignant phenotypes of GBM cells.Copyright © 2021 Elsevier Inc. All rights reserved.

20 keywords...

hide…